News

TPG Biotech previously invested $12.8 million in the Company, and along with the Company’s angel investors, has financed the Company since inception. The Company plans to use the

The allowed patent claims contain both composition and method of treatment claims that will broadly cover all of InSite’s bromfenac product candidates, including BromSite ((bromfenac 0.075%) ophthalmic solution

This partnership will launch the Aprecia brand, as well as provide comprehensive commercialization of Aprecia’s pioneering technology platform and initial pharmaceutical products. Aprecia is the first and only

The new collaboration agreement, designated OPeRA (Organ Protection & Replacement Institute), includes pre-clinical research and development programs as well as clinical phase II programs, providing NeuroVive with access

The trial is designed to evaluate the long-term safety and efficacy of GCS-100 in patients who completed the initial 12-week Phase II study (GCS-100-CS-4002). In the 4003 extension

The partnership employs KineMed’s new dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways. KineMed president, co-founder and chief science officer

Both the companies have not disclosed the financial terms of the agreement. Genmab chief executive officer Jan van de Winkel said the company is happy to enter its

The product, which is available in the 5mg and 10mg strengths, is indicated for the treatment of narcolepsy and attention deficit disorder with hyperactivity. The company received final

The company said that results were also observed in patients with ALK+ NSCLC who entered the trial with brain metastases. Seoul National University Hospital lead investigator Dong-Wan Kim